| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1131: Obinutuzumab with mycophenolate mofetil for treating lupus nephritis |
|
Medicine details |
|
| Medicine name | obinutuzumab (Gazyvaro®) |
| Formulation | solution for infusion. |
| Reference number | 4836 |
| Indication | in combination with mycophenolate mofetil (MMF) is indicated for the treatment of adult patients with active Class III or IV, with or without concomitant Class V, lupus nephritis |
| Company | Roche Products Ltd |
| BNF chapter | Immunological products & vaccines |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 22/01/2026 |
| NICE guidance | TA1131: Obinutuzumab with mycophenolate mofetil for treating lupus nephritis |